Summary of Envista Holdings Corporation Q1 2026 Earnings Call

1Key Financial Results and Metrics

Sales: $706 million, with a 9.5% core growth year-over-year. Adjusted gross margin increased to 55.8%, up 100 basis points.

Adjusted EBITDA: Increased by 25% year-over-year, with margins of 14%, a 120 basis point improvement.

Adjusted EPS: Rose to $0.36, up 50% from the previous year.

Free Cash Flow: Negative $16 million, typical for Q1, with expectations of approximately 100% free cash flow conversion for 2026.

Tax Rate: Non-GAAP tax rate at 26.1%, with an expected full-year rate around 28%.

2Strategic Updates and Business Highlights

Core Growth: All major business segments reported positive growth, with ortho consumables and diagnostics up double digits, while implants grew mid-single digits (excluding China).

Investments: Increased spending in sales, marketing, and R&D, with a focus on new product launches, including the Nobel S Series in implants and Spark in orthodontics.

Acquisition: Completed an accretive tuck-in acquisition of Versah, enhancing the implants portfolio with a novel preparation technique.

Employee Engagement: Continued improvements in employee engagement and community impact initiatives, including support for underserved patients.

3Forward Guidance and Outlook

2026 Guidance: Reaffirmed core growth of 2% to 4%, adjusted EBITDA growth of 7% to 13%, and EPS of $1.35 to $1.45.

Share Repurchase Program: An additional $300 million authorized for share repurchases, allowing for approximately one-third of annual free cash flow to be allocated to buybacks.

4Bad News, Challenges, or Points of Concern

Geopolitical Risks: Ongoing tensions in the Middle East have raised concerns, although minimal direct impact on the dental market has been observed so far.

China Market: Facing challenges due to anticipated Value-Based Pricing (VBP) processes, leading to significant declines in implant sales in China.

Free Cash Flow: Negative cash flow in Q1 raises concerns about liquidity, though expected to normalize throughout the year.

Market Volatility: The company remains cautious about macroeconomic uncertainties, which could affect future performance.

5Notable Q&A Insights

Market Resilience: Management expressed confidence in the dental market's resilience despite macro challenges, emphasizing a well-balanced portfolio.

Pricing Strategy: The company plans to maintain its pricing strategy, which has been effective in the past, while being prepared to adjust if inflationary pressures increase.

VBP Impact: Management confirmed that the VBP process in China is expected to start in Q2 or Q3, with potential short-term revenue compression but long-term benefits anticipated.

Innovation Focus: Continued emphasis on new product development as a key driver for future growth, with a strong pipeline of innovations expected to support market share gains. Overall, Envista Holdings reported a strong start to 2026 with solid financial performance, strategic investments in growth, and a commitment to navigating macroeconomic challenges while maintaining a focus on innovation and customer engagement.